Purdue Research Foundation (PRF) announces a six-month "Innovation Assessment Process" that is designed to expedite the transfer of life-changing Purdue discoveries to the public. Under the new guidelines, Purdue innovators who file a qualified technology disclosure with the Office of Technology Commercialization (OTC) will receive a decision within six months on whether OTC will continue commercialization support of the disclosed innovation. Should OTC decline to continue commercialization support, the innovator(s) may request a reconveyance of the intellectual property at that time.

This commitment supports speed, fairness and transparency in the technology disclosure procedure and pertains to innovations that are not encumbered with outside obligations. The process is outlined below.

**Invention Assessment Process**

- Purdue innovators should disclose their innovation(s) to OTC for evaluation and protection. The disclosure form can be found at [http://otc-prf.org/webform/invention-disclosure](http://otc-prf.org/webform/invention-disclosure)
- Once a complete description of the technology including utility and commercial application (i.e., the qualified technology disclosure) is received, OTC is committed to a six-month assessment period during which a market assessment and IP analysis will be performed. More information about the six-month review process can be found at [http://otc-prf.org/commercialization-assessment](http://otc-prf.org/commercialization-assessment)
- The internal assessment period starts on the day the qualified technology disclosure is received on a technology.
- On or before expiration of the six-month assessment period, the Purdue innovator(s) will be provided with OTC’s decision on continuing or discontinuing commercialization support.
- In the instances in which OTC decides to continue commercialization support, a material action will be taken, such as filing a patent application, registering a copyright, securing protection for a tangible research property, or negotiating an option or license. Should the technology produce "Net Proceeds" to PRF, Purdue University policy I.A.1 on cost recovery and royalty disbursements as outlined at [http://www.purdue.edu/policies/academic-research-affairs/ia1.html](http://www.purdue.edu/policies/academic-research-affairs/ia1.html) will apply.
- In those instances in which OTC decides to discontinue commercialization support, the submitting Purdue innovator(s) will be provided an opportunity to request reconveyance of the intellectual property title back to the innovators in accordance with Purdue University policy.

We are committed to making Purdue-based startups attractive for faculty and investors while amplifying Purdue’s impact and ability to move life-changing technologies to our global society. For additional information on OTC's commercialization process visit [http://otc-prf.org/technology-transfer/commercialization-processes](http://otc-prf.org/technology-transfer/commercialization-processes)